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Background and purpose: To report single institution’s IGRT and dosimetry analysis on the 37 Gy/5 fraction
prostate SBRT clinical trial.
Materials/methods: The IRB (Duke University Medical Center) approved clinical trial has treated 28 patients with
stage T1-T2c prostate cancer with a regimen of 37 Gy in 5 fractions using IMRT and IGRT protocols since 2009. The
clinical trial protocol requires CT/MRI imaging for the prostate delineation; a margin of 3 mm in posterior direction
and 5 mm elsewhere for planning target volume (PTV); and strict dose constraints for primary organs-at-risks (OARs)
including the bladder, the rectum, and the femoral heads. Rigid IGRT process is also an essential part of the
protocol. Precise patient and prostate positioning and dynamic tracking of prostate motion are performed with
electromagnetic localization device (Calypso) and on-board imaging (OBI) system. Initial patient and target
alignment is performed based on fiducials with OBI imaging system and Calypso system. Prior to treatment, cone-
beam CT (CBCT) is performed for soft tissue alignment verification. During treatment, per-beam corrections for
target motion using translational couch movements is performed before irradiating each field, based on
electromagnetic localization or on-board imaging localization. Dosimetric analysis on target coverage and OAR
sparing is performed based on key DVH parameters corresponding to protocol guidance. IGRT analysis is focused
on the average frequency and magnitude of corrections during treatment, and overall intra-fractional target drift. A
margin value is derived using actual target motion data and the margin recipe from Van Herk et al., and is
compared to the current one in practice. In addition, cumulative doses with and without per-beam IGRT corrections
are compared to assess the benefit of online IGRT.
Results: 1. No deviation has been found in 10 of 14 dosimetric constraints, with minor deviations in the rest 4 constraints.
2. Online IGRT techniques including Calypso, OBI and CBCT supplement each other to create an effective and reliable
system on tracking target and correcting intra-fractional motion.
3. On average ½ corrections have been performed per fraction, with magnitude of (0.22 ± 0.11) cm. Average target drift
magnitude is (0.7 ± 1.3) mm in one direction during each fraction.
4. Benefit from per-beam correction in overall review is small: most differences from no correction are < 0.1 Gy for PTV
D1cc/Dmean and < 1%/1.5 cc for OAR parameters. Up to 1.5 Gy reduction was seen in PTV D99% without online
correction. Largest differences for OARs are −4.1 cc and +1.6 cc in the V50% for the bladder and the rectum, respectively.
However, online IGRT helps to catch unexpected significant target motion.
5. Margin derived from actual target motion is 2.5 mm isotropic, consist with current practice.
Conclusions: Clinical experience of the 37 Gy/5-fraction prostate SBRT from a single institution is reported. Dosimetric
analysis demonstrated excellent target coverage and OAR sparing for our first 28 patients in this trial. Online IGRT
techniques implemented are both effective and reliable. Per-beam correction in general provides a small benefit in
dosimetry. Target motion measured by online localization devices confirms that current margin selection is adequate.
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In the last decade investigators from across the globe
have examined a number of hypo-fractionated regimens
for prostate radiation treatment, with daily fraction sizes
ranging from 2.5 to 7.25 Gy delivered in 5–28 fractions
over 1–6 weeks [1]. During the same period, a number
of studies have been published that suggest that the
α/ß ratio of prostate cancer may be in the range of
1.2 – 3.0 Gy [2]. In addition, it has also been suggested
that the α/β ratio for late rectal toxicity (primarily
bleeding) is in the range of 4–5 Gy [3]. If these hypoth-
eses are indeed true then treating prostate cancer with
fewer, larger fraction (to a lower total dose) may result
in an increase in the therapeutic ratio [1]. Therefore, a
new treatment paradigm is warranted for clinical inves-
tigation, assume it will not only limit the volume of nor-
mal tissue irradiated by using tighter margins but will
also greatly decrease the overall treatment time and may
provide a biologic basis to decrease rectal toxicity. It is
hypothesized that hypo-fractionated radiation therapy
using continuous real-time evaluation of prostate mo-
tion may offer the ability to reach each of these goals by
limiting radiation dose to surrounding normal tissues
while optimizing treatment to the prostate and taking
advantage of differences in prostate cancer and normal
tissue responses to radiation therapy to improve upon
the therapeutic ratio.
The five-fraction prostate stereotactic-body radiation
therapy (SBRT) protocol is developed under this hypoth-
esis. Previously, several five-fraction prostate SBRT regi-
mens has been developed and evaluated by clinicians
and researchers at other institutions, and treatment out-
comes were promising [4]. The 1st experience of five-
fraction regimen for prostates was reported by Virginia
Mason Clinic in 2006 [5]. A total of 40 patients with
low risk prostate cancer were treated with 6.7 Gy per
fraction. Bolzicco et al. [6] reported on treating 45
low-and intermediate-risk prostate cancer patients with
Cyberknife® SBRT at the regimen of 35 Gy in five fractions.
Katz et al. from Winthrop University Hospital, NY [7]
reported a study with 304 patients all treated with 5
fractions using Cyberknife®. Total doses are 35 Gy for
the 1st 50 patients and 36.25 Gy for the rest. Freeman
and King [8] reported five-year outcomes on 41 low-risk
prostate cancer patients receiving SBRT with CyberKnife®
with total dose of 35–36.25 Gy in five fractions. Alongi
et al. [9] reported a phase II study on linac-based prostate
SBRT with VMAT technique based on 40 patients. The
prescription is 35 Gy in 5 fractions. In terms of treatment
outcome, no > Grade 3 toxicity was reported in any of
the previous studies. Patients were reported to tolerate
the SBRT treatment well, with biochemical control rate
between 93% to 100% depends on the length of the
median follow-up.In this report, we present our experience of the insti-
tutional prostate SBRT clinical trial, with a focus on tar-
get motion statistics and the IMRT/IGRT techniques we
implemented, and their combined impact on dosimetry.
Materials and method
Patient data and treatment planning
From 2009 to 2012, 28 stage T1-2 prostate cancer pa-
tients were enrolled in the IRB approved institutional
SBRT clinical trial. Patients receive 5 fractions of radi-
ation with each fraction size of 7.4 Gy and the total dose
of 37 Gy. The 5 treatments are scheduled to be deliv-
ered every other day. A minimum of 36 hours and a
maximum of 96 hours should separate each treatment.
No more than 3 fractions will be delivered per week.
The total duration of treatment will be no shorter than
10 days and no longer than 18 days.
Patients are asked to have a full bladder during simula-
tion and daily treatment. Patients are given instructions
to drink 16–24 oz of water or other fluid 2–3 hours prior
to treatment and to not urinate between this time and
treatment as they are able. For rectum filling management,
patients are instructed to take one tablespoon of Milk
of Magnesia the night and one Fleet’s enema 2–3 hours
before the simulation and each treatment.
Computed Tomography (CT) is the primary image set
for treatment planning. The simulation is performed in
the supine treatment position, with immobilization de-
vice (alpha-cradle) to minimize body motion and rotation.
Axial cuts of 1.25 mm are acquired throughout the pelvis
for the accuracy of marker identification and localization.
Magnetic resonance imaging (MRI) is also acquired and
fused with CT images to assist target delineation. MRI is
acquired prior to Calypso transponder implantation to
exclude artifacts interfering with soft tissue contouring.
For fiducial markers, MRI is acquired in the same day of
planning CT to minimize patient visit to the clinic.
CT and MRI image sets are registered for the delinea-
tion of target volumes and OARs. The definition of vol-
umes is in accordance with the ICRU Report #50 and
ICRT Report #62: Prescribing, Recording, and Reporting
Photon Beam Therapy [10,11]. The gross tumor volume
(GTV) for the purposes of this protocol is the prostate
only, and is defined by the physician based on the plan-
ning CT and MR along with clinical information. The
clinical target volume (CTV) is the same as the GTV. The
planning target volume (PTV) is defined as the CTV plus
a 3 mm posteriorly and 5 mm in all other dimensions.
IMRT planning is performed in Eclipse® Treatment Plan-
ning System (Varian Medical Systems, Palo Alto, CA). 7 or
9 co-planar beams are used to deliver dose distribution
that is highly conformal to the PTV while maximally
spare adjacent OARs. The plans are normalized so that
the prescription isodose line covers at least 95% of the
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are listed in Table 1.
Imaging-guidance and dynamic tracking techniques
This SBRT protocol requires stereotactic treatment
with the use of a 3-D coordinate system defined by
implanted electromagnetic transponders or implanted
fiducial markers. The initial localization and alignment
is based on the center of mass of the transponders/
fiducial markers. Prior to treatment, kV CBCT is also
acquired for soft-tissue alignment verification and de-
formation review. Significant rotations or soft tissue de-
formations will be corrected at initial localization stage,
and intra-fractional rotations are ignored. After initial
localization is performed, all effort is made to initiate
the treatment delivery as quickly as possible. Continu-
ous tracking and adjustment of target position during
treatment is achieved by translational shifting the center
of mass determined via electromagnetic transponders or
fiducial markers, using remote couch movement. Specific-
ally, per-beam couch corrections is made, if necessary,
based on the actual target motion provided by dynamic
tracking with either Calypso or per-beam kV orthogonal
imaging with OBI. A correction action is performed if the
target migrated more than 3 mm in any of three orthog-
onal coordinates.
To analyze the IGRT effectiveness, the motion correc-
tion magnitude and frequency of each treatment fraction
are pooled and analyzed. The overall drifting magnitude
during treatment is also captured and used to perform
the margin evaluation based on the margin recipe
described by Van Herk et al. [12].
Dosimetric benefit of dynamic tracking and online
correction is evaluated by comparing delivered dose dis-
tributions with and without such correction. The dose
distribution without correction is generated in the same
treatment planning system by accumulating doses withoutTable 1 Key dosimetric constraints used in the IMRT
planning of this protocol
Target (PTV) D1cc ≤ 43.0 Gy
Dmean > 37.0 Gy
Bladder D1cc < 40.7 Gy
V37 Gy < 2 cc
V24 Gy < 40 cc
Rectum D1cc ≤ 39.3 Gy
V37 Gy < 2 cc
V33 Gy < 25% volume
V28 Gy < 40% volume
V24 Gy < 50% volume
Femoral Heads V20 Gy < 10 cc
D1cc < 30 Gyonline correction from each beam. The difference in dos-
imetry between actual treatment with online IGRT and
simulated treatment without per-beam online corrections
is used to quantify the benefit of using dynamic tracking
and correction. The dosimetric analysis was based on ori-
ginal planning CT and contours.
Results and discussions
Treatment plan Dosimetry
The dosimetry of 28 treatment plans and their compli-
ance to the protocol constraints are summarized in
Table 2. The CTV is very well covered for all 28 patients.
Majority of dosimetric parameters are well within proto-
col constraints (Table 1); no constraints are exceeded in
PTV and femoral heads. For the rectum, 1 case has Dmax
exceeding constraint value 39.3 Gy by 0.03 Gy; and 3 cases
have V37 Gy exceeding constraint value 2 cc by 0.08,
0.60 and 0.02 cc, respectively. For the bladder, 1 case
has V24 Gy exceeding constraint value 40 cc by 4.6 cc;
and 18 cases have V37 Gy exceeding constraint 2 cc by
(3.1 ± 3.1) cc.
IGRT analysis and margin evaluation
For the total of 28 patients, 25 were setup based on with
Calypso and 3 were setup based on with OBI. Among
the 25 Calypso cases, 4 patients had at least 1 or more
fractions switched to OBI imaging due to technical
issues. 5 (out of 28) patients had transponder/seed migra-
tion that was captured by Calypso/OBI or CBCT imaging
and their corresponding locations were adjusted and mon-
itored by CBCT. Figure 1 shows an example of such case.
3 (out of 28) patients (1 fraction each) had significant
motion or soft tissue deformation that led to the treat-
ment halt for that specific fraction. One had to wait till
full bladder and empty rectum; one had muscle spasm
that caused sudden large body motion and was able to
maintain position after break; and one had unexplain-
able large body motion during treatment and was able
to maintain position after communications and further
instructions. Overall, the combination of Calypso, OBI
and CBCT IGRT options not only supplements each
other with their own unique advantages, but also helps
to guarantee uninterrupted treatment when one option
is not available.
Online correction frequency per fraction is summarized
in the histogram in Figure 2. Nearly 70% of fractions
are treated without corrections; and ~90% fractions have
less than 2 online corrections performed during treat-
ment. On average 0.5 corrections have been performed
per fraction.
The correction magnitudes in three directions (vertical,
longitudinal and lateral) are shown in the first three box
plots of the Figure 3, and the combined vector length
of corrections are shown in the “Combined” boxplot.
Table 2 Key dosimetric parameter statistics
Structure volume Key DVH parameters statistics # of patients w/minor deviations Deviation amount
CTV (53.6 ± 24.1) cc Dmean (102.4 ± 1.1) Gy N/A N/A
Dmax (104.8 ± 1.7) Gy
Dmin (100.2 ± 1.4) Gy
D99% (100.2 ± 1.0) Gy
PTV (98.8 ± 36.8) cc D1cc (39.1 ± 0.6) Gy 0
Dmean (37.9 ± 0.3) Gy 0
D99% (36.1 ± 0.5) Gy 0
CI (RTOG) (0.99 ± 0.02) 0
Bladder (228 ±144) cc Dmax (38.6 ± 0.5) Gy 0
V37 Gy (3.6 ± 3.0) cc 18 (3.1 ± 3.1) cc
V24 Gy (20.0 ± 10.8) cc 1 4.6 cc
Rectum (69.1 ± 27.0) cc Dmax (38.3 ± 0.6) Gy 1 0.03 cc
V37 Gy (1.0 ± 0.7) cc 3 0.08, 0.02, 0.6 cc
V33 Gy (4.3 ± 2.1) cc 0
V28 Gy (8.7 ± 3.6) cc 0
V24 Gy (11.2 ± 4.7) cc 0
Femoral Heads - D1cc (17.8 ± 2.70) Gy 0
V20 Gy (0.3 ± 1.3) cc 0
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with the lateral direction having the smallest correction
range, and the longitudinal (superior-inferior) direction
having the largest correction range. The combined
correction magnitude from all three directions is (0.22
± 0.11) cm.Fraction 1 F
Fraction 3
Figure 1 Calypso transponder shifted position over the course of trea
whose location relative to the patient is somewhat arbitrary for each fractioThe total couch shift from the start to the end of each
treatment represents the target position drift. Histo-
grams and statistical test results of target drift in three
directions are shown in Figure 4. The magnitude is lar-
ger than corresponding values in Figure 3 because it
shows the cumulative drift of the target during eachraction 2
Fraction 4
tment. The grid-like patterns in each image are the Calypso antenna,
n.
Figure 2 Histogram of per-fraction online correction frequency.
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direction, whereas lateral drifts are the smallest. Although
occasional drifts > 0.3 cm can be seen, the Wincoxon
Signed-Rank test reveals that drifts in none of the three
directions are statistically significant.
In additional to the statistics above, the necessary
margin for this specific patient group is calculated based
on the target drift data described above and the margin
recipe by Van Herk et al. [12]. The directional margins
for AP/LR/SI directions are 2.5/1.0/1.7 mm; and the
isotropic margin is 2.5 mm. This calculated margin size
confirms that the protocol margin selection is sufficient.Figure 3 Boxplots of online correction magnitude in vertical, longitud
in quadrature).Dynamic tracking benefits analysis
Figure 5 shows the difference in multiple dosimetric
parameters between the simulated treatment without
online corrections and the actual treatment that includes
the dynamic tracking and correction. In general, when
looking at the cumulative dose over 5 fractions, the benefit
from per-beam correction is small for all dosimetric pa-
rameters corresponding to the protocol constraints. The
per-beam correction has very small impacts on CTV
coverage: key CTV dosemetric parameters without cor-
rections are all within ± 0.5 Gy (1.4%) from those calcu-
lated with per-beam corrections. Differences from noinal and lateral directions, as well as combined length (added
Figure 4 Histograms and Wincoxon Signed-Rank test results of target position drifts in Lateral, Vertical and Longitudinal directions.
Figure 5 Differences in key dosimetric parameters between actual treatment with online IGRT and simulated treatment without
per-beam correction.
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for both RTOG [13,14] and Paddick [15] conformity
indices. Slightly higher difference is seen for PTV D99%:
0.6 to 1.5 Gy reductions are found for 5 patients without
online correction. For the bladder, the majority of patients
have < 1%/1.5 cc difference between with and without
corrections, with only 2 patients having differences
of −3%/-4.1 cc and +1.5%/+3.7 cc respectively. Similar
distribution has been observed for the rectum: the
majority has < 1%/< 0.7 cc difference, with exceptions
of 4 patients having differences ranging from −1.7%/-1.1 cc
to +4.6%/1.6 cc. Very small differences (< 0.9 Gy/< 0.4 cc)
are also seen for the femoral heads dosimetric parameters.
In general, only 1–2 patients (4-7%) would see >1%/1 cc
increase in OARs irradiated volumes if no online cor-
rection was made. The rigorous supportive measures on
bladder and rectum management that patients follow
on each fraction and precise initial soft-tissue based tar-
get alignment have helped to minimize the motion during
the radiation treatment. The variation could be larger
and more frequent without these steps. The small diffrence
between treating with and without online IGRT can be
attributed to two other important components in the
protocol. One is the carefully constrcucted immobolization
device that helps to minimize the inter-fraction and the
intra-fraction external patient body motion and rotation.
Therefore, the online IGRT can be focused on tracking and
correcting internal organ motion. With patient education
and instruction, the internal motion as obseverd, can be
kept to a small range and overall target drfiting is small too.
On the other hand, the dynamic tracking helps to catch
the significant motion in those 3 patients/fractions that
requires beam off/treatment halt. Currently, there is no
clear indication on complete prevention of such sudden
motion, thus the dynamic tracking is still beneficial to
ensure the patient is treated with high precision through
each beam irradiation.
In this study all dosimetric analysis was performed on
the planning CT and original contours. In reality patient’s
anatomy is dynamic and could change from day to day;
therefore more accurate dosimetric analysis could be
achieved if daily anatomical information is taken into
consideration through online imaging modalities such
as CBCT. However at current stage, due to the suboptimal
image quality of CBCT images and lacking of a reliable
deformable image registration tool, accurate cumulative
dose analysis of the bladder and the rectum using daily
anatomy is still difficult to achieve. We are actively work-
ing towards this goal though in-house algorithm develop-
ment and close collaborations with vendors.
Conclusion
This report summarizes our first 3 year experiences on
a 37 Gy/5-fraction prostate SBRT clinical trial, with afocus on target motion statistics and the IMRT/IGRT
techniques we implemented, as well as their combined
impact on dosimetry. Dosimetric analysis demonstrated
excellent target coverage and OAR sparing for our first 28
patients in this trial. The majority of DVH parameters are
well within protocol constraints. Online dynamic track-
ing with Calypso and/or OBI is both reliable and effect-
ive, resulting in 0.49 target position corrections per
treatment fraction. These per-beam corrections provide
a small benefit in dosimetry, but help to retain target
coverage when large target motion occurs. Target mo-
tion measured by online localization devices is generally
small, and confirms that the current margin selection is
adequate. Future protocol analysis will include GI/GU
toxicity and disease-free survival when follow up time
is sufficient.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
WRL is the PI of the clinical trial and the attending physician who supervised
treatments in the study, including approving the treatment plans and all
soft-tissue matching during the IGRT process. QJW is the co-investigator and
the physicist of the clinical trial, in charge of data collection, treatment
planning and IGRT/online monitoring components. TL performed data
collection, analysis and simulation of treatments without online corrections.
LY and FFY both contributed to data collection and analysis. All authors
contributed to drafting the manuscript. All authors read and approved the
final manuscript.
Received: 28 March 2013 Accepted: 3 September 2013
Published: 13 September 2013
References
1. Miles EF, Lee WR: Hypofractionation for prostate cancer: a critical review.
Semin Radiat Oncol 2008, 18(1):41–47.
2. Fowler JF: The radiobiology of prostate cancer including new aspects of
fractionated radiotherapy. Acta Oncol 2005, 44(3):265–276.
3. Fowler JF, et al: What hypofractionated protocols should be tested for
prostate cancer? Int J Radiat Oncol Biol Phys 2003, 56(4):1093–1104.
4. Arcangeli S, Scorsetti M, Alongi F: Will SBRT replace conventional
radiotherapy in patients with low-intermediate risk prostate cancer?
A review. Critical Rev Oncol/hematol 2012, 84(1):101–108.
5. Madsen BL, et al: Stereotactic hypofractionated accurate radiotherapy
of the prostate (SHARP), 33.5 Gy in five fractions for localized
disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007,
67(4):1099–1105.
6. Bolzicco G, et al: Image-guided stereotactic body radiation therapy for
clinically localized prostate cancer: preliminary clinical results. Technol Cancer
Res Treat 2010, 9(5):473–477.
7. Katz AJ, et al: Stereotactic body radiotherapy for organ-confined prostate
cancer. BMC Urol 2010, 10:1.
8. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate
cancer: five-year outcomes. Radiation Oncol 2011, 6:3.
9. Alongi F, et al: Linac based SBRT for prostate cancer in 5 fractions with
VMAT and flattening filter free beams: preliminary report of a phase II
study. Radiation Oncol 2013, 8(1):171.
10. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy.
Bethesda, MD: International Commission on Radiation Units and
Measurements; 1993.
11. ICRU Report 62: Prescribing, recording, and reporting photon beam therapy
(supplement to ICRU report 50). Bethesda, MD: International Commission on
Radiation Units and Measurements; 1999.
12. van Herk M: Errors and margins in radiotherapy. Semin Radiat Oncol 2004,
14(1):52–64.
Wu et al. Radiation Oncology 2013, 8:215 Page 8 of 8
http://www.ro-journal.com/content/8/1/21513. Feuvret L, et al: Conformity index: a review. Int J Radiat Oncol Biol Phys
2006, 64(2):333–342.
14. Shaw E, et al: Single dose radiosurgical treatment of recurrent previously
irradiated primary brain tumors and brain metastases: final report of
RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 2000, 47(2):291–298.
15. Paddick I: A simple scoring ratio to index the conformity of radiosurgical
treatment plans. Technical note. J Neurosurg 2000, 93(Suppl 3):219–222.
doi:10.1186/1748-717X-8-215
Cite this article as: Wu et al.: Single Institution’s Dosimetry and IGRT
Analysis of Prostate SBRT. Radiation Oncology 2013 8:215.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
